Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Mar;29(3):281–287. doi: 10.1111/j.1365-2125.1990.tb03637.x

The effects of a single dose of dilevalol on [3H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations.

L G Howes 1, P R Rowe 1, H Krum 1, W J Louis 1
PMCID: PMC1380127  PMID: 2310652

Abstract

1. A single oral dose of dilevalol (200 mg or 400 mg) or placebo was administered to 15 normal male volunteers in a double-blind, random order crossover study. 2. Dilevalol had no significant effect on supine blood pressures or heart rates, but caused a significant fall in systolic blood pressure 1 and 30 min following standing, and attenuated the rise in diastolic blood pressure and heart rate that accompanies standing. 3. Dilevalol caused a dose dependent increase in plasma noradrenaline levels from arterialized blood which was due to an increase in noradrenaline spillover with no change in clearance. 4. Dilevalol increased plasma levels of the noradrenaline metabolite 3,4-dihydroxyphenylethylene glycol (DHPG) (which is formed in sympathetic nerves following neuronal uptake of noradrenaline), indicating that the increase in noradrenaline spillover was not due to the blockade of neuronal uptake. 5. Acute dilevalol administration had no effect on total plasma cholesterol, HDL-cholesterol or LDL-cholesterol levels.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Best J. D., Halter J. B. Blood pressure and norepinephrine spillover during propranolol infusion in humans. Am J Physiol. 1985 Apr;248(4 Pt 2):R400–R406. doi: 10.1152/ajpregu.1985.248.4.R400. [DOI] [PubMed] [Google Scholar]
  2. Esler M., Jackman G., Bobik A., Kelleher D., Jennings G., Leonard P., Skews H., Korner P. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci. 1979 Oct 22;25(17):1461–1470. doi: 10.1016/0024-3205(79)90371-0. [DOI] [PubMed] [Google Scholar]
  3. Fuji Y., Suzuki H., Katsumata H., Nakajima S., Saruta T. Hormonal and renal responses to oral once-daily calcium entry blocker in normotensive and hypertensive persons. J Cardiovasc Pharmacol. 1988 Apr;11(4):438–443. doi: 10.1097/00005344-198804000-00009. [DOI] [PubMed] [Google Scholar]
  4. Goldstein D. S., Eisenhofer G., Stull R., Folio C. J., Keiser H. R., Kopin I. J. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988 Jan;81(1):213–220. doi: 10.1172/JCI113298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hooper P. L., Woo W., Visconti L., Pathak D. R. Terbutaline raises high-density-lipoprotein-cholesterol levels. N Engl J Med. 1981 Dec 10;305(24):1455–1457. doi: 10.1056/NEJM198112103052406. [DOI] [PubMed] [Google Scholar]
  6. Howes L. G., Louis W. J. Effects of antihypertensive drugs on cardiovascular risk factors. Clin Exp Pharmacol Physiol. 1988 Mar;15(3):199–202. doi: 10.1111/j.1440-1681.1988.tb01062.x. [DOI] [PubMed] [Google Scholar]
  7. Howes L. G., Rowe P. R. Combined cation exchange-alumina extraction of [H3]noradrenaline for the determination of [H3]noradrenaline plasma kinetics in man. Scand J Clin Lab Invest. 1987 Nov;47(7):749–750. doi: 10.1080/00365518709168941. [DOI] [PubMed] [Google Scholar]
  8. Howes L. G., Summers R. J., Rowe P. R., Louis W. J. The simultaneous determination of 3,4-dihydroxyphenyl-ethylene glycol, 3,4-dihydroxyphenylacetic acid and catecholamines in brain tissue by high performance liquid chromatography with electrochemical detection. Neurosci Lett. 1983 Aug 8;38(3):327–332. doi: 10.1016/0304-3940(83)90390-7. [DOI] [PubMed] [Google Scholar]
  9. Kennedy I., Levy G. P. Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals. Br J Pharmacol. 1975 Apr;53(4):585–592. doi: 10.1111/j.1476-5381.1975.tb07398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Louis W. J., Christophidis N., Brignell M., Vijayasekaran V., McNeil J., Vajda F. J. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust N Z J Med. 1978 Dec;8(6):602–609. doi: 10.1111/j.1445-5994.1978.tb04847.x. [DOI] [PubMed] [Google Scholar]
  11. Matsunaga K., Nakamura K., Ueda M. Intrinsic beta-sympathomimetic activity of dilevalol, R, R-isomer of labetalol. J Pharmacobiodyn. 1985 Sep;8(9):785–787. doi: 10.1248/bpb1978.8.785. [DOI] [PubMed] [Google Scholar]
  12. Mulvihill-Wilson J., Gaffney F. A., Pettinger W. A., Blomqvist C. G., Anderson S., Graham R. M. Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine. Circulation. 1983 Feb;67(2):383–393. doi: 10.1161/01.cir.67.2.383. [DOI] [PubMed] [Google Scholar]
  13. Tarlov S. R., Langer S. Z. The fate of 3 H-norepinephrine released from isolated atria and vas deferens: effect of field stimulation. J Pharmacol Exp Ther. 1971 Nov;179(2):186–197. [PubMed] [Google Scholar]
  14. Vincent H. H., Boomsma F., Man in't Veld A. J., Derkx F. H., Wenting G. J., Schalekamp M. A. Effects of selective and nonselective beta-agonists on plasma potassium and norepinephrine. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):107–114. [PubMed] [Google Scholar]
  15. Wallin J. D., Cook M. E., Clifton G. G., Blasucci D. J., Poland M. Intravenous dilevalol. Effects of the R-R optical isomer of labetalol in patients with severe hypertension. Arch Intern Med. 1988 Mar;148(3):534–538. doi: 10.1001/archinte.148.3.534. [DOI] [PubMed] [Google Scholar]
  16. Ziegler M. G., Chernow B., Woodson L. C., Coyle J., Cruess D., Lake C. R. The effect of propranolol on catecholamine clearance. Clin Pharmacol Ther. 1986 Jul;40(1):116–119. doi: 10.1038/clpt.1986.147. [DOI] [PubMed] [Google Scholar]
  17. Zschiedrich H., Neurohr W., Lüth J. B., Philipp T., Distler A. Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. Klin Wochenschr. 1983 Jul 1;61(13):661–667. doi: 10.1007/BF01487583. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES